Empagliflozin Provides Consistent Benefit in HFrEF, Regardless of Diuretic Use
Data from the EMPEROR-Reduced trial provide insight into the effects of empagliflozin in patients with heart failure with reduced ejection fraction based on baseline diuretic use from the phase 3 trial.
Nitishk Dhingra University Of Toronto Division Of Cardiac Surgery For St Patients With Heart Failure Reduced Ejection Fraction Cardiac Surgery
Source: hcplive.com